ライフサイエンスコーパス: ADR

1 ADR >=25% was significantly associated with ileal intuba

2 ADR (number of procedures in which at least one adenoma

3 ADR and advanced-ADR were 33.00% (95% CI: 29.52-36.54) a

4 ADR could be improved by recommending a withdrawal time

5 ADR induces enzymatic cleavage of DAF from podocyte surf

6 ADR was the primary strategy in 30% (n=88/292), of which

7 ADR-1 promotes SLO-2 function not by editing the transcr

8 ADR-associated major events occurred in 3.4% (n=10/292).

9 ADR-expressing T cells resist cellular rejection by targ

10 ADR-related hospital readmissions were similar in both g

11 ADRs were evaluated following EAACI guidelines.

12 erimental groups: Control (C), C+ADR, Dose 1+ADR, and Dose 2+ADR.

13 : Control (C), C+ADR, Dose 1+ADR, and Dose 2+ADR.

14 n (N=90), retrograde wire escalation (N=24), ADR (N=35), and retrograde dissection and reentry (N=44)

15 rine) infusion at 320 ng kg(-1) min(-1) (320 ADR), and (2) with vagal blockade (2 mg atropine), befor

16 A-aDO2 increased by 6 +/- 2 mmHg during 320 ADR and by 5 +/- 2 mmHg during ATR + 80 ADR, and the cha

17 During 320 ADR cardiac output (QT) and pulmonary artery systolic pr

18 A-aDO2 increased by 12 +/- 7 mmHg during 320 ADR, and by 9 +/- 6 mmHg during ATR + 80 ADR, and the ch

19 A total of 432 ADRs in 133 (69%) patients were recorded, 64% local and

20 oxicity against MCF-7/ADR cells, lower MCF-7/ADR cell viability and higher apoptotic cells.

21 h the increase of cytotoxicity against MCF-7/ADR cells, lower MCF-7/ADR cell viability and higher apo

22 then characterized and incubated with MCF-7/ADR human breast cancer cells and followed by US exposur

23 doxorubicin in the multidrug resistant MCF-7/ADR xenografted nude mice.

24 istant (MDR) breast cancer cell lines (MCF-7/ADR).

25 ficantly increased; however, during ATR + 80 ADR only QT was significantly increased, yet blood flow

26 e infusion at 80 ng kg(-1) min(-1) (ATR + 80 ADR).

27 320 ADR, and by 9 +/- 6 mmHg during ATR + 80 ADR, and the change in calculated Q VA /QT was +2% in bo

28 320 ADR and by 5 +/- 2 mmHg during ATR + 80 ADR, and the change in calculated Q VA /QT was +2% in bo

29 to its intended pharmacologic target (type A ADR) or an unintended target (type B ADR).

30 in (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.

31 provides a viable strategy to mitigate acute ADR induced cardiotoxicity.

32 Adriamycin (ADR) is an anticancer agent that increases oxidative str

33 lA by the chemotherapeutic agent adriamycin (ADR), but not NF-kappaB activation induced by tumor necr

34 n and in glomerular podocytes in adriamycin (ADR) nephropathy, remnant kidney after 5/6 renal ablatio

35 rols disease in murine models of adriamycin (ADR)-induced focal and segmental glomerulosclerosis (FSG

36 odocyte number in the setting of Adriamycin (ADR)-induced nephropathy.

37 ADR and advanced-ADR were 33.00% (95% CI: 29.52-36.54) and 13.18% (95% CI

38 6o-3p by antagomiR, either prior to or after ADR injection, substantially restored WT1, alleviated po

39 mining techniques facilitated computer-aided ADR analysis of drug labeling.

40 ated a prototype approach for computer-aided ADR monitoring and studies which can be applied to other

41 Although ADR has become very rare with cART due to new potent the

42 Although ADR is associated inversely with interval colorectal can

43 Although ADR is rare and declining in California, its costly cons

44 extends our knowledge on the interplay among ADRs and reveals their complexity in defense regulation.

45 he highest quintile ADR category (such as an ADR > 24.56%) decreased the adjusted hazard ratios for i

46 3 and nearly 5 times less likely to cause an ADR than clindamycin.

47 tively 6 and 3 times less likely to cause an ADR than the other penicillins, penicillin V and amoxici

48 Ranked from least to most likely to cause an ADR, antibiotics most commonly prescribed were as follow

49 ly mild), and 78.9% and 48.1% experienced an ADR (mostly mild or moderate oral reactions).

50 METHODS AND Patients were selected if an ADR strategy was applied.

51 2-4.0), failure (3.7; 95% CI, 1.1-12.6), and ADR (10.0; 95% CI, 2.1-46.7) in arms with thrice weekly

52 mice were exposed to acute doses of ADR and ADR with mRQ.

53 rk for enhancing the predictions of DDIs and ADR types by integrating drug-gene interactions (DGIs).

54 nts were microbiologic failure, relapse, and ADR in patients on either DOT or SAT.

55 s and variables associated with CRC risk and ADR.

56 treatment-emergent AE (TEAE), AESI, SAE, and ADR occurrences.

57 antly associated with failure of therapy and ADR in patients.

58 al efficacy [38.2%], inefficacy [26.5%], and ADRs [22.8%]).

59 discontinuation, followed by inefficacy and ADRs.

60 co-expressing chimeric antigen receptors and ADRs persisted in mice and produced sustained tumor erad

61 endoscopists (74.5%) increased their annual ADR category.

62 the whole data set to categorize the annual ADRs for each endoscopist.

63 st frequent serious cephalosporin-associated ADRs were Clostridium difficile infection within 90 days

64 (type A ADR) or an unintended target (type B ADR).

65 Immunologically mediated type B ADRs, such as drug hypersensitivity syndrome, drug react

66 at risk for immunologically mediated type B ADRs.

67 nd adequate support of these patients before ADR will prevent treatment failure and HIV-1 transmissio

68 ose, reversed the oxidative damage caused by ADR, on both protein and lipid levels in all three organ

69 ave four experimental groups: Control (C), C+ADR, Dose 1+ADR, and Dose 2+ADR.

70 state or underestimate the impact of certain ADRs to the public health.

71 armacological, pharmacokinetic, and clinical ADR profiles of methylphenidate, aripiprazole, and rispe

72 The most common ADRs occurred locally in the oral cavity and were catego

73 hnique compared with CrossBoss in controlled ADR and retrograde dissection and reentry (0.93+/-0.69 v

74 The Controlled ADR (ie, combined CrossBoss-Stingray) subtype was applie

75 and reentry in ADR compared with controlled ADR (Stingray) or limited antegrade subintimal tracking

76 ined were microbiological sputum conversion, ADR, and relapse.

77 CV-ADR often occurred early after ibrutinib administration.

78 nent (IC) to determine whether CV-ADR and CV-ADR deaths were associated with ibrutinib.

79 Importantly, CV-ADR were associated with fatalities that ranged from ~10

80 ze cardiovascular adverse drug reactions (CV-ADR) associated with ibrutinib.

81 ation component (IC) to determine whether CV-ADR and CV-ADR deaths were associated with ibrutinib.

82 mple reports of thalidomide causing a deadly ADR when used against myeloma, a likely result of the di

83 elf-administered therapy (SAT) in decreasing ADR, microbiologic failure, and relapse in meta-analyses

84 ing information or package inserts, describe ADRs.

85 a model in which during neural development, ADR-2 levels overcome ADR-1 repression, resulting in inc

86 SNI-1 also enhanced ADR or cisplatin inhibition of murine TNBC tumors in viv

87 Several reported studies have extracted ADRs from labeling documents, but most, if not all, did

88 ng and had the lowest reported rate of fatal ADRs (0.1/million prescriptions) and overall ADRs (21.5/

89 0.2%-9.90%) vs 0.9% (95% CI, 0.4%-2.3%) for ADR, respectively.

90 r relapse .01 (95% CI, -.03 to .06), and for ADR 0.0 (95% CI, -0.01 to 0.01).

91 ty normalization is a promising approach for ADR extraction from drug labels.

92 e-control study to identify risk factors for ADR in all patients starting their first cART in the Swi

93 Here, we characterized risk factors for ADR, to improve patient care and prevent emergence of dr

94 Incidence rates for ADRs causing hospital admission ranged from 0.4% to 10.3

95 erlying molecular mechanisms can emerge from ADR co-analysis.

96 Data from ADRs reported to various pharmacovigilance databases wer

97 One strain was confirmed to have ADR, 2 were confirmed as causing exogenous reinfection,

98 n and control groups developed a hematologic ADR (7.4% vs 7.9%; relative risk, 0.93; 95% confidence i

99 ervention group (2.6%) developed hematologic ADRs compared with patients in the control group (22.9%)

100 there was a 10-fold reduction in hematologic ADRs among variant carriers who were identified and rece

101 outcomes were the occurrence of hematologic ADRs (leukocyte count < 3.0*10(9)/L or reduced platelet

102 the proportions of patients with hematologic ADRs during thiopurine treatment for IBD.

103 ly explained by an innovation effect (higher ADRs among incoming colonoscopists than among leaving co

104 ime incidence decreased with lower to higher ADRs (26.6; 95% CI, 20.0-34.3 for quintile 1 vs 12.5; 95

105 particularly interested in understanding how ADRs might be better detected, assessed and avoided.

106 Doxorubicin hydrochloride (ADR) is an anthracycline antibiotic used to treat variou

107 pproach, used for normalizing the identified ADR mentions to MedDRA terms, is based on an extension o

108 Therefore, systematically identifying ADR information from drug labels is critical in multiple

109 of host genetics, microbes, and drugs in IM-ADR development; expand on the existing models of IM-ADR

110 lopment; expand on the existing models of IM-ADR pathogenesis to address multiple unexplained observa

111 cell-mediated and primary T cell-mediated IM-ADRs.

112 d MB-MMX led to an absolute 8.5% increase in ADR, compared with placebo, without increasing the remov

113 Compared with no increase in ADR, reaching or maintaining the highest quintile ADR ca

114 try using subintimal tracking and reentry in ADR compared with controlled ADR (Stingray) or limited a

115 models were used to examine the variation in ADR with withdrawal time and extent of examination, and

116 We observed a strong increase in ADRs from 2003 through 2012 in Germany.

117 Incident ADR was estimated to have ranged from 0.3% (95% confiden

118 The colonoscopy quality indicators including ADR were calculated, and patient factors associated with

119 An increased ADR was associated with an adjusted hazard ratio for int

120 An increased ADR was defined as an increase by at least 1 quintile ca

121 p = 0.0047) was associated with an increased ADR, as well as smoking, older age, higher BMI and male

122 r Screening Program, we associated increased ADR with a reduced risk of interval colorectal cancer an

123 ome ADR-1 repression, resulting in increased ADR-2 binding and editing of specific transcripts.

124 re used to evaluate the effects of increased ADR on the risk of interval colorectal cancer and death.

125 eal-time colonoscopy significantly increases ADR and adenomas detected per colonoscopy without increa

126 l cancer death, the effects of an increasing ADR have not been shown.

127 We investigated whether increasing ADRs from individual endoscopists is associated with red

128 esistant mouse strain to adriamycin-induced (ADR-induced) focal segmental glomerulosclerosis (FSGS).

129 tridium) difficile infections pivotal to its ADR profile.

130 We successfully predict previously known ADRs for drugs prescribed to cutaneous diseases, and are

131 pharmacokinetics; and iv) DDIs without known ADRs.

132 meeting strict failure criteria had a lower ADR (OR 0.30; 95% CI: 0.12-0.77).

133 Several features of T cell-mediated ADRs are strikingly similar to those displayed by patien

134 sing and searching predictive small-molecule/ADR connections.

135 human ovarian adenocarcinoma cell line, NCI-ADR/Res (NAR), over expressing the targeted gene and pre

136 ion of the P-glycoprotein-overexpressing NCI-ADR-RES and Messa/Dx5MDR cell lines.

137 ely, knockdown of endogenous testisin in NCI/ADR-Res ovarian tumor cells reduces PAR-2 N-terminal pro

138 = 0.0159 muM), ovarian cancer cell line NCI/ADR-RES (GI(5)(0) = 0.0169 muM), and renal cancer cell l

139 pressing multi-drug-resistant cell lines NCI/ADR-RES and Messa/Dx5.

140 d A2780PAR) but not cisplatin-resistant (NCI/ADR-RES and A2780CP20) ovarian cancer cells.

141 bine, vinblastine, and paclitaxel in the NCI/ADR-RES and Messa/Dx5 cell lines, which overexpress P-gl

142 A cytotoxicity assay with NCI/ADR-RES, a drug resistant cell line, suggested that PEG5

143 and are also able to identify promising new ADRs.

144 nificantly worse rates of fatal and nonfatal ADRs associated with other penicillins and alternatives

145 n had the highest rate of fatal and nonfatal ADRs of any of the antibiotics commonly prescribed by de

146 Rs) and 32 spontaneously reported nonserious ADRs were submitted, approximately half of which are ide

147 back pain, 3,620 (7.7%) had a reported NSAID ADR.

148 Patients with listed NSAID ADRs also had higher odds of a documented opioid prescri

149 ts with chronic back pain and reported NSAID ADRs are at a higher risk of developing OUD and receivin

150 score-matched analysis, patients with NSAID ADRs had higher odds (odds ratio, 1.34; 95% CI, 1.07-1.6

151 ing OUD as compared with those without NSAID ADRs.

152 Healthy mice were exposed to acute doses of ADR and ADR with mRQ.

153 med an unbiased assessment of the effects of ADR-2, the only A-to-I editing enzyme in C. elegans, on

154 le maintaining or increasing the efficacy of ADR against cancer cell lines in vitro.

155 ance were associated with a low frequency of ADR.

156 rule-based system for the identification of ADR entity mentions in the text of drug labels and their

157 The annual incidence of ADR declined over the study period.

158 ADR), and secular trends in the incidence of ADR were assessed.

159 All the animals received an injection of ADR, except half of the control group, which were given

160 In mouse model of ADR nephropathy, overexpression of miR-466o-3p inhibited

161 regimens in patients, and expected rates of ADR, as well as a proposal of new susceptibility breakpo

162 ystem achieved 77.0% F1 score on the task of ADR mention recognition and 82.6% micro-averaged F1 scor

163 82.6% micro-averaged F1 score on the task of ADR normalization, while rule-based system achieved 67.4

164 r and varies by drug, as well as the type of ADR.

165 ngdom) aims to evaluate the value and use of ADR and determine its future position in contemporary ch

166 tudies reported rates ranging from 7%-98% of ADRs being either definitely/possibly avoidable.

167 , and illustrate how comparative analysis of ADRs can reveal underlying mechanisms.

168 nsidered a risk marker to the development of ADRs to immunotherapy.

169 /or form reactive metabolites, are devoid of ADRs.

170 cogenomics have been applied to the field of ADRs for both predictable ADRs and hypersensitivity drug

171 In postapproval experience, the frequency of ADRs spontaneously reported was less than 1 per 10,000 d

172 d between the subgroups but the incidence of ADRs was decreased in the lower body weight subgroup.

173 wer for every 5 percentage-point increase of ADRs and for mortality, 12.8% (95% CI, 11.1%-13.7%) lowe

174 sitized the patients and the total number of ADRs (P = 0.004) occurred locally (P = 0.003) and system

175 significantly improve the predictability of ADRs.

176 im of this study was to quantify the risk of ADRs associated with oral antibiotics commonly prescribe

177 dverse Reactions (AR), where the severity of ADRs are intended to decrease in the order of BW > WP >

178 and extend to postmarketing surveillance of ADRs in real-world populations.

179 ribing in England, and the rate and types of ADRs associated with them.

180 T2DM has an effect on ADR after controlling for multiple confounding variables

181 from a community-based health care system on ADR variation and cancer risk among 57,588 patients exam

182 iated with either microbiological failure or ADR in the clinic.

183 reventing microbiologic failure, relapse, or ADR, in evidence-based medicine.

184 Our ADR in both genders meets and exceeds the recommended co

185 Bail-out ADR strategies were successful in 63% (n=133/210).

186 ul restoration of drug sensitivity of OVCAR8/ADR cells to Pgp-transportable cytotoxic agents.

187 In 2012, overall ADR reached 31.3% and 20.1% in men and women, respective

188 The overall ADR was 9.1% (95% CI 8.5-9.8; 755 of 8256 procedures), v

189 ADRs (0.1/million prescriptions) and overall ADRs (21.5/million prescriptions).

190 ng neural development, ADR-2 levels overcome ADR-1 repression, resulting in increased ADR-2 binding a

191 onal criterion involving P-gp overexpressing ADR-RES cells.

192 ed to the field of ADRs for both predictable ADRs and hypersensitivity drug reactions.

193 s) and overall (337.3/million prescriptions) ADRs, with Clostridiodes (formerly Clostridium) difficil

194 g interactions (DDI) is necessary to prevent ADR, the rapid pace of drug discovery makes it challengi

195 a machine learning classifier to prioritize ADRs for approved drugs and pre-clinical small-molecule

196 t cardiomyocytes (H9C2) showed that RES:QUE: ADR at 10:10:1 ratio was synergistic in SKOV-3 cells and

197 reaching or maintaining the highest quintile ADR category (such as an ADR > 24.56%) decreased the adj

198 The adenoma detection rate (ADR) is an important quality indicator of screening colo

199 2 min, and quarterly Adenoma Detection Rate (ADR) ranging from 50 to 70% for both male and female pat

200 The adenoma detection rate (ADR) was 19.4%, with a higher rate in men (25.8% vs 16.7

201 significant improved adenoma detection rate (ADR), however, self-reported CIR may be overestimated an

202 mance is measured by adenoma detection rate (ADR).

203 nd its impact on the adenoma detection rate (ADR).

204 actors affecting the adenoma detection rate (ADR).

205 primary outcome was adenoma detection rate (ADR, the percentage of patients with at least 1 histolog

206 denoma or carcinoma (adenoma detection rate [ADR]).

207 pective analysis of adenoma detection rates (ADR) in initial screening colonoscopies to further inves

208 ed to calculate the adenoma detection rates (ADR), and assess the quality of colonoscopies in an oppo

209 ity, as measured by adenoma detection rates (ADRs), varies widely among physicians, with unknown cons

210 efficacy, inefficacy, adverse drug reaction (ADR), and other medical causes.

211 Adverse drug reactions (ADRs) accounted for the majority of drug substitutions o

212 sly reported serious adverse drug reactions (ADRs) and 32 spontaneously reported nonserious ADRs were

213 dverse events (AEs), adverse drug reactions (ADRs) and immunological response (IgE, IgG4) were evalua

214 LA associations with adverse drug reactions (ADRs) and one for the examination of infectious and auto

215 Adverse drug reactions (ADRs) are a central consideration during drug developmen

216 Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery

217 Adverse drug reactions (ADRs) are a relatively common cause of morbidity and mor

218 Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of preventable morbi

219 Adverse drug reactions (ADRs) are commonplace and occur when a drug binds to its

220 Adverse Drug Reactions (ADRs) are of great public health concern.

221 investigate whether adverse drug reactions (ADRs) during immunotherapy with a grass extract (AVANZ(R

222 self-reported NSAID adverse drug reactions (ADRs) on risk of OUD, adjusting for other relevant clini

223 Adverse drug reactions (ADRs) pose critical public health issues, affecting over

224 ious AEs (SAEs), and adverse drug reactions (ADRs) reported during postinjection visits and investiga

225 Adverse drug reactions (ADRs) requiring closer monitoring or change to treatment

226 companies can report adverse drug reactions (ADRs) to pharmacovigilance databases.

227 1 is associated with adverse drug reactions (ADRs), including hepatotoxicity; oxidative metabolism of

228 ts experienced minor adverse drug reactions (ADRs), of which 2 cases demonstrated flap necrosis.

229 medication can cause adverse drug reactions (ADRs), unwanted or unexpected events, which are a major

230 the investigators as adverse drug reactions (ADRs).

231 incidence of serious adverse drug reactions (ADRs).

232 d timing of onset of adverse drug reactions (ADRs).

233 etects, and prevents adverse drug reactions (ADRs).

234 iated with a risk of adverse drug reactions (ADRs).

235 py because of severe adverse drug reactions (ADRs); leukopenia is one of the most serious ADRs.

236 We investigated adrenergic receptor (ADR) beta2 desensitization by administering oral ADRbeta

237 Our alloimmune defense receptor (ADR) selectively recognizes 4-1BB, a cell surface recept

238 ns of gene variants in adrenergic receptors (ADRs) with GAD, with the involvement of stressful events

239 pharmacogenomics and their role in reducing ADRs, especially those caused by drug hypersensitivity r

240 evices for antegrade dissection and reentry (ADR) of chronic total occlusions has improved historical

241 scalation, antegrade dissection and reentry (ADR), and retrograde dissection and reentry.

242 sing its importance; correlation of reported ADRs with public events, regulatory announcements, and w

243 and suppression of acquired drug resistance (ADR) and informed predictions about optimal clinical dos

244 le of adherence in acquired drug resistance (ADR) and that very high levels of nonadherence are neede

245 lure, relapse, and acquired drug resistance (ADR) for 4 dosing schedules: daily throughout, thrice we

246 ciency virus type 1 (HIV-1) drug resistance (ADR) has fallen dramatically since introduction of combi

247 ing treatment, and acquired drug resistance (ADR) in patients with HIV and active tuberculosis.

248 cs associated with acquired drug resistance (ADR), and secular trends in the incidence of ADR were as

249 tures to ascertain acquired drug resistance (ADR).

250 to generate over 50 novel amidino-rocaglate (ADR) and amino-rocaglate derivatives.

251 he same therapeutic category shared the same ADR patterns in BW (e.g., nervous system drug class is h

252 0.6% of patients; 5.2% experienced a serious ADR.

253 losporin-associated allergy, and all serious ADRs.

254 ith a specific emphasis on analyzing serious ADRs presented in BW, which is of most drug safety conce

255 phalosporin-associated "allergy" and serious ADRs.

256 he MedDRA System Organ Class levels, serious ADRs (sADRs) from BW were prevalent in Nervous System di

257 ADRs); leukopenia is one of the most serious ADRs.

258 eaving colonoscopists, and relatively stable ADRs among continuing colonoscopists).

259 , further work is needed to address how such ADRs may be prevented.

260 FDA-approved drug labeling summarizes ADRs of a drug product mainly in three sections, i.e., B

261 This is the first study showing that ADR variants are susceptibility factors for GAD, further

262 Biochemical data suggest that ADR-1, a deaminase-deficient member of the adenosine dea

263 The ADR for gastroenterologists was higher than for nongastr

264 The ADR is lower in patients meeting strict criteria for fai

265 The ADR technique was used in 23% (n=292/1253) of the RECHAR

266 The ADR types were adapted from a DDI corpus, including i) a

267 The ADR was 11.5% (95% CI 10.6-12.5; 493 of 4299 procedures)

268 The ADR was higher for the MB-MMX group (273 of 485 patients

269 The ADR was significantly higher in the CADe group (54.8%) t

270 identified predictors for CS failure and the ADR.

271 We assessed trends in the ADR in the first 10 years of the German screening colono

272 , outcomes, and low complication rate of the ADR technique and its subtypes confirm the benefit and v

273 Additional information relating to the ADR was collected: associated drug classification; clini

274 The ADRs for gastroenterologists and nongastroenterologists

275 roach achieves an F-score of 0.87 across the ADRs classification using only the DDI features.

276 and systematically analyzed and compared the ADRs from the three labeling sections with a specific em

277 ll, did not discriminate the severity of the ADRs by the different labeling sections.

278 s been implicated in the pathogenesis of the ADRs.

279 the adr1 triple mutant, suggesting that the ADRs are required for TNL downstream signaling.

280 ing initiation with colonoscopy according to ADR quintiles (averages 15.3%, quintile 1; 21.3%, quinti

281 expression was induced early in response to ADR in mice and cultured human podocytes, and prevented

282 Many factors can contribute to ADRs, including genetics.

283 The degree to which genetics contributes to ADRs is not entirely clear and varies by drug, as well a

284 increased hazard of drug substitution due to ADRs.

285 ally lower rate of drug substitutions due to ADRs.

286 athioprine exhibited the highest DR owing to ADRs.

287 ine was associated with a higher DR owing to ADRs.

288 We used ADR quintiles in the whole data set to categorize the an

289 127 micelles (mRQ) when co-administered with ADR, will be cardioprotective in vitro and in vivo, whil

290 CI, 1.2-5.5]; P = .012) were associated with ADR in the multivariable model.

291 ting on RNA (ADAR) family, is competing with ADR-2 for binding to specific transcripts early in devel

292 l and cecal intubation for endoscopists with ADR >=25 and < 25%, respectively.

293 es indicated that mRQ did not interfere with ADR caspase activity in SKOV-3 cells but significantly d

294 between baseline isolates and isolates with ADR.

295 Concurrent administration of mRQ with ADR at 10:10:1 ratio provides a viable strategy to mitig

296 hemical estimations the presence of mRQ with ADR conferred full cardioprotection in these mice.

297 urrent dosing of these natural products with ADR is limited due to their low solubility, and low oral

298 y reported therapeutic class associated with ADRs in children admitted to hospital (17 studies; 12 st

299 were frequently reported as associated with ADRs in outpatient children (13 studies; 6 studies respe

300 utic classes most frequently associated with ADRs, further work is needed to address how such ADRs ma